Histogenics and ProChon Biotech merge

May 16, 2011 by MassDevice staff

Histogenics Corp. and Prochon Biotech Ltd. merge in an all-stock deal that will see former ProChon head Patrick O'Donnell installed as Histogenics' new CEO.

Histogenics, ProChon Biotech

A pair of Bay State regenerative medicine firms, Histogenics Corp. and ProChon Biotech Ltd., merged in an all-stock deal that brings ProChon CEO Patrick O'Donnell into the Histogenics corner office.

O'Donnell told MassDevice.com that a deal has been in the works since the early part of 2011.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.